Corneal rejection is an immunological complication that can occur after a corneal transplant (penetrating keratoplasty (PKP) or lamellar keratoplasty (DALK). It is the leading cause of graft failure and requires early detection and urgent treatment.
✔ Red eye (conjunctival hyperemia).
✔ Eye pain (mild to severe).
✔ Sudden blurred vision.
✔ Photophobia (sensitivity to light).
✔ Excessive tearing.
🔹 Inflammatory infiltrates in the graft (lymphocytes attacking the tissue).
🔹 Corneal edema (thickening and loss of transparency).
🔹 Keratic precipitates (deposits of immune cells on the endothelium).
🔹 Corneal neovascularization (growth of blood vessels into the graft).
🔹 Endothelial rejection line (visible with a slit lamp).
Prevention is key, especially in the first 2 years post-transplant:
High doses initially, gradually tapering.
Some patients require long-term therapy (years).
Cyclosporine, tacrolimus.
Ocular trauma (contact sports).
Untreated infections (ocular herpes).
Loose or infected sutures.
Periodic slit-lamp examinations and endothelial microscopy.
The transplant success rate depends on multiple factors:
PKP (Penetrating Keratoplasty): 70-80%
Lamellar Keratoplasty: 85-90% (lower rejection due to preserving the patient's endothelium)
Younger patients: Higher risk of rejection (more active immune system)
Neovascularized corneas: Reduced survival (50-60%)
Anatomical survival: The graft remains transparent.
Functional survival: The patient achieves useful vision (20/40 or better).
See an ophthalmologist urgently (rejection is reversible if treated promptly).
Increase the frequency of corticosteroid drops (e.g., prednisolone every hour).
Oral immunosuppressant therapy (in severe cases).
80% of rejections occur in the first year post-transplant.
Lamellar keratoplasties have a lower rejection rate than PKP.
Long-term use of topical corticosteroids reduces the risk of rejection by 50%.